Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo

@article{Wang2008BortezomibIS,
  title={Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo},
  author={M Wang and Xiang Hua Han and L Zhang and Jing Yang and J F Qian and Ying Kang Shi and Larry W. Kwak and Jorge E Romaguera and Qing Yi},
  journal={Leukemia},
  year={2008},
  volume={22},
  pages={179-185}
}
Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma with poor clinical outcome. Although front therapy induces a high rate of complete remission (CR), relapse is inevitable and new regimens are much needed for relapsed MCL. The proteasome inhibitor bortezomib (BTZ) induces apoptosis and sensitizes MCL cells to chemotherapy in relapsed MCL, but CR rates are low, with a short duration of response and severe toxicity. Here we evaluated whether BTZ is additive or synergistic with… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Similar Papers

Loading similar papers…